Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, 6th Floor - 6410, Durham, NC 27701
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Alam, I., R. Manch, S. Naggie, R. Reindollar, J. Slim, A. Prabhakar, K. Lauwers, et al. “P0826 : Effectiveness of simeprevir (SMV)-containing regimens among patients with chronic hepatitis C virus (HCV) in various us practice settings: Interim analysis of the sonet study.” In Journal of Hepatology, 62:S646–47. Elsevier BV, 2015. https://doi.org/10.1016/s0168-8278(15)31029-1.

Full Text

Naggie, Susanna, Imtaiz Alam, Richard A. Manch, Robert Reindollar, Jihad Slim, Avi Prabhakar, Kris Lauwers, et al. “Effectiveness of Simeprevir (SMV) - Containing Regimens Among Patients With Chronic Hepatitis C Virus (HCV) in Various US Practice Settings: Interim Analysis of the Sonet Study.” In Gastroenterology, 148:S1090–S1090. W B SAUNDERS CO-ELSEVIER INC, 2015.

Scholars@Duke

Matthews, G. V., J. Neuhaus, S. Bhagani, S. H. Mehta, E. Vlahakis, M. Doroana, S. Naggie, et al. “Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial..” Hiv Med 16 Suppl 1 (April 2015): 129–36. https://doi.org/10.1111/hiv.12241.

PMID
25711331
Full Text

Naggie, Susanna, and Arthur Y. Kim. “PHOTON-2: hope for patients with HIV and HCV co-infection?.” Lancet 385, no. 9973 (March 21, 2015): 1052–54. https://doi.org/10.1016/S0140-6736(15)60122-2.

PMID
25659286
Full Text

Meissner, Eric G., Yu-Jin Lee, Anu Osinusi, Zayani Sims, Jing Qin, Dan Sturdevant, John McHutchison, et al. “Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients..” Hepatology 61, no. 3 (March 2015): 790–801. https://doi.org/10.1002/hep.27424.

PMID
25203718
Full Text

Norton, Brianna, and Susanna Naggie. “The clinical management of HCV in the HIV-infected patient..” Antivir Ther 20, no. 5 (2015): 457–67. https://doi.org/10.3851/IMP2910.

PMID
25346056
Full Text

Sulkowski, Mark S., Susanna Naggie, Jacob Lalezari, Walford Jeffrey Fessel, Karam Mounzer, Margaret Shuhart, Anne F. Luetkemeyer, et al. “Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection..” Jama 312, no. 4 (July 23, 2014): 353–61. https://doi.org/10.1001/jama.2014.7734.

PMID
25038354
Full Text

Molina, J. M., S. Naggie, M. Sulkowski, J. Lalezari, J. Mchutchison, D. Dieterich, and M. Rodriguez-Torres. “[In Process Citation]..” Med Mal Infect 44, no. 6 Suppl (June 2014): 1–2. https://doi.org/10.1016/S0399-077X(14)70041-1.

PMID
24994128
Full Text

Naggie, S., M. Sulkowski, A. Gaggar, L. Stamm, L. Ni, D. Brainard, W. Symonds, J. McHutchison, D. Dieterich, and M. Rodriguez-Torres. “P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS.” In Journal of Hepatology, 60:S475–76. Elsevier BV, 2014. https://doi.org/10.1016/s0168-8278(14)61333-7.

Full Text

Norton, B. L., C. I. Voils, S. H. Timberlake, E. J. Hecker, N. D. Goswami, K. M. Huffman, A. Landgraf, S. Naggie, and J. E. Stout. “Community-based HCV screening: Knowledge and attitudes in a high risk urban population.” Bmc Infectious Diseases 14, no. 1 (March 10, 2014). https://doi.org/10.1186/1471-2334-14-74.

Full Text

Pages